News Headlines Article

New hepatitis C drugs’ price prompts an ethical debate: Who deserves to get them?
Washington Post

Simple math shows the challenge facing U.S. taxpayers, patients and insurers following the launch late last year of two expensive new drugs to treat hepatitis C.

If all 3 million people estimated to be infected with the virus in the United States were treated with the drugs, at an average cost of $100,000 per person, the amount spent for all prescription drugs in the country would double, from about $300 billion in a year to more than $600 billion.

Commands